分享 收藏

Recombinant Human BCMA/TNFRSF17

品牌：翌圣生物
产地：
供应商报价：面议

翌圣生物科技(上海)股份有限公司更新时间：2024-12-24 09:03:45

销售范围售全国

入驻年限第1年

营业执照已审核

同类产品肿瘤坏死因子(11件)

立即扫码咨询

联系方式：400-611-1883

联系我们时请说明在仪器网（www.yiqi.com）上看到的!

扫码分享

为您推荐

详细介绍

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF receptor superfamily. It is a type III membrane protein containing one extracellular cysteine rich domain. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. TNFRSF17 can binds to TNFSF13B/BLyS/BAFF and TNFSF13/APRIL, and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

Product Properties

Synonyms	TNFRSF17, BCM, CD269
Accession	Q02223
GeneID	608
Source	E.coli-derived Human BCMA/TNFRSF17, Ala5-Ala54.
Molecular Weight	Approximately 5.4 kDa.
AA Sequence	AGQCSQNEYF DSLLHACIPC QLRCSSNTPP LTCQRYCNAS VTNSVKGTNA
Tag	None
Physical Appearance	Sterile Filtered White lyophilized (freeze-dried) powder.
Purity	> 98% by SDS-PAGE and HPLC analyses.
Biological Activity	The ED₅₀ as determined by its ability to inhibit APRIL-mediated proliferation of anti-IgM stimulated murine B cells is no less than 40 ng/mL, corresponding to a specific activity of > 2.5 × 10⁴ IU/mg in the presence of 100 ng/mL human APRIL. Fully biologically active when compared to standard.
Endotoxin	< 1.0 EU per 1μg of the protein by the LAL method.
Formulation	Lyophilized from a 0.2 μm filtered concentrated solution in 30% acetonitrile, 0.1% TFA.
Reconstitution	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.